Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

ACC's new CEO John Lewin: Former California Medical Association CEO John Lewin, MD, assumes the role of chief executive at the American College of Cardiology in September, following ACC's move to Washington, D.C. While at CMA, Lewis led the acquisition of a continuing medical education firm in order to better educate group members. Prior to CMA, the exec founded MEDePass to provide internet confidentiality for physicians. Lewin also oversaw Hawaii's department of health...

You may also be interested in...



Steven Niedelman steps down

Deputy Associate Commissioner for Regulatory Operations announces he will retire from FDA at the end of June to become Executive VP at Quintiles Consulting. Niedelman began his career at FDA in 1972 as a consumer safety officer. Before taking the ORA post in 2002, he served as acting director of the Office of Enforcement, where he started as deputy director in July 2001. Early this year, Niedelman was named to a team charged with prioritizing device center initiatives and overseeing the implementation of CDRH's postmarket transformation (1"The Gray Sheet" Jan. 23, 2006, p. 5)...

Orthofix Aims For Acquisitions To Boost Sagging Reconstruction Business

Orthofix is looking to acquire a firm or license technology in the spine reconstruction area to buoy its reconstruction business and capitalize on the strong growth seen in the spine sector

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023710

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel